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Condensed abstract: Obesity is a risk factor for post-menopausal breast cancer, and many women 
diagnosed with breast cancer, irrespective of menopausal status, gain weight post diagnosis.  
Weight management plays an important role in rehabilitation and recovery since obesity and/or 
weight gain may lead to poorer quality of life, overall health and/or survival.    
 
Abstract (170 words) 
Overweight and obesity are risk factors for post-menopausal breast cancer, and many women 
diagnosed with breast cancer, irrespective of menopausal status, gain weight after diagnosis.  
Weight management plays an important role in rehabilitation and recovery since obesity and/or 
weight gain may lead to poorer breast cancer prognosis, as well as prevalent co-morbid 
conditions (e.g. cardiovascular disease and diabetes), poorer surgical outcomes (e.g., increased 
operating and recovery times, higher infection rates, and poorer healing), lymphedema, fatigue, 
functional decline, and poorer health and overall quality of life.  Health care professionals should 
encourage weight management at all phases of the cancer care continuum as a means to 
potentially avoid adverse sequelae and late effects, as well as to improve overall health and 
possibly survival.  Comprehensive approaches that involve dietary and behavior modification, 
and increased aerobic and strength training exercise have shown promise in either preventing 
weight gain or promoting weight loss, reducing biomarkers associated with inflammation and co-
morbidity, and improving lifestyle behaviors, functional status, and quality of life in this high-
risk patient population.              
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Introduction 
Worldwide, obesity and breast cancer represent two common diseases, both with increasing 
prevalence,1 and each independently having a profound impact on public health. There also is a 
well-established relationship between the two diseases, with most large epidemiological studies 
demonstrating an increased risk of developing post-menopausal breast cancer in overweight or 
obese women (as determined by weight, body mass index [kg/m2] or waist/hip circumference 
ratio).2-6  Further, changes in weight throughout adulthood may influence breast cancer risk.7-10  
specifically, post-menopausal breast cancer risk is elevated among those who have experienced 
weight gain throughout adulthood, while weight loss after menopause has been associated with 
reduced risk. 7-10  Interestingly and in contrast to breast cancer that occurs later in life, obesity 
does not generally contribute to risk of breast cancer that occurs premenopause,3-5 though 
interactions between age of onset, race, and BRCA mutation and subtype status are beginning to 
emerge and complicate these simple associations.11;12 Given that breast cancer is a disease 
associated with aging with risk highest after menopause,13 and those who are overweight or 
obese in their younger years are likely to remain overweight or obese as they age,14 it is not 
surprising that more than one in two women diagnosed with breast cancer are overweight or 
obese.15     
 
Weight gain following the diagnosis of breast cancer 
Weight gain is common in both pre- and post-menopausal women following diagnosis.16-19    In 
some of the first studies that documented weight gain more than two decades ago, weight gains 
of up to 11 kg. were noted in 1-out-of-4 women receiving adjuvant chemotherapy.20;21  In more 
recent years; however, and as oncologists have become more aware of this prevalent side effect 
and have counselled patients to avoid weight gain, post-diagnosis weight gains have diminished, 
but still can range up to 5.0 kgs.22-24   Such weight gains have been demonstrated in both 
retrospective 25;26, and prospective studies, 18;22;24;27-36  as well as during and after a variety of 
adjuvant treatments, such as chemotherapy, 22;27-31;33;35 radiotherapy,31;35 and endocrine therapy,32 
and experienced over periods as short as six months28 and as long as 5 years 26.  Unfortunately, 
these weight gains also tend to be accompanied by adverse changes in body composition; 
specifically, gains in fat mass, particularly central fat,22 and in the presence of either no change 
or declines in fat-free mass (muscle).19;23;24;27;28;31;33;35;37 This type of weight gain has been 
termed sarcopenic obesity,19;38 and has significant and adverse functional implications, such as 
reduced muscular strength and mobility.   
 
Mechanisms of weight gain 
The pathophysiological basis of weight gain following breast cancer remains unclear.   
Chemotherapy treatment has been considered a significant contributory factor through reduced 
metabolism as a consequence of treatment-induced ovarian failure and the subsequent rapid 
onset of menopause,18 as well as reductions in physical activity post-diagnosis.24;31;39  However, 
it has been suggested that with the advent of newer chemotherapeutic regimens involving shorter 
treatment schedules, that the incidence of weight gain following breast cancer may have 
declined.23  Inconsistent relationships have been observed between weight gain following breast 
cancer and age, menopausal status, and/or body mass index at diagnosis.39  Findings from 
population-based, prospective cohort studies are needed to help better understand the likely 
contributory factors to weight gain in the context of current treatment regimens and in differing 
breast cancer populations.  Irrespective of the pathophysiologic basis, weight gain reflects an 
imbalance between energy intake and energy expenditure,22 and the reasons for this imbalance 
have been explored.  There is some evidence to support declines in total energy expenditure, by 
reductions in resting energy expenditure 22;27 and/or reductions in energy expenditure attributed 
to physical activity 27;31 during and following treatment. Mixed findings have been observed for 
energy intake, with some studies showing declines,27 while others show energy intake remains 
unchanged;31;35 few studies however provide data showing that caloric consumption increases 
over baseline levels.    
 
Implications of overweight and obesity and/or weight gain at diagnosis and throughout the 
course of survivorship on disease-free and overall survival 
Upon diagnosis, being overweight or obese elevates risk (up to 4-fold) of developing multiple 
other diseases such as type II diabetes, asthma, chronic back pain, osteoarthritis, and 
cardiovascular disease,40;41 and this risk may be elevated further as a consequence of receiving 
treatment.18;42;43  In fact, women with breast cancer are just as likely, if not more, to die from 
heart disease as their breast cancer.40;44 Results from a recent meta-analysis also demonstrate that 
obesity is associated with poorer overall and breast cancer-specific survival.45  The meta-analysis 
included results from 43 studies which enrolled women diagnosed with breast cancer between 
1963 and 2005, with sample sizes ranging from 100 to 424,168.  Results show that obese women 
are at higher risk of all-cause (HR=1.33, 95% CI: 1.21, 1.47) and breast cancer specific 
(HR=1.33, 95% CI: 1.19, 1.50) mortality when compared to non-obese women with breast 
cancer.  Moreover, differentials in rates of survival have varied, and have appeared to be 
dependent on the following factors (though it should be noted that some of these confidence 
intervals overlap): 1) index of obesity used, e.g., BMI (HR=1.33; 1.23, 1.44) versus waist-hip 
ratio (HR=1.31; 1.14, 1.50); 2) menopausal status, e.g., pre-menopausal (HR-1.47; 1.19, 1.83) 
versus post-menopausal (HR=1.22; 0.95, 1.57); 3) diagnosis date, e.g., before 1995 (HR=1.31; 
1.16, 1.46) versus afterward (HR=1.49; 1.31, 1.68); and 4) study mode, i.e., data from treatment 
(HR=1.22; 1.14, 1.31) versus observational (HR=1.36; 1.23, 1.44) studies.   
Studies of the prognostic consequences of weight change post-diagnosis have yielded 
inconsistent findings.  Some studies have shown increased rates of recurrence, as well as disease-
specific and all-cause mortality;20;34;46;47  whereas others have not  observed such 
relationships.26;48;48;49  Moreover, j-shaped curves as originally reported by Goodwin et al,17 
which show increased disease-specific mortality with BMI, have been supported by the recent 
findings of Nichols et al.47 Chen et al.50and Thivat et al.46  Such findings support the need for 
weight management strategies post –diagnosis.40 
While speculation exists that weight loss following a diagnosis may lead to survival 
benefits among women who are overweight,45;51 there has yet to be a prospective study to answer 
this research question. However, an NIH-funded vanguard trial entitled,  ENERGY trial 
(Exercise and Nutrition to Enhance Recovery and Good Health in You), is underway to explore 
the feasibility of this approach and to obtain precision estimates for a larger study.  Given that 
overweight and obese breast cancer survivors are more likely, at the point of diagnosis, to have 
diabetes and cardiovascular disease, as well as other obesity-related conditions, such as 
osteoarthritis, or gallbladder and gastro-esophageal reflux disease or are more likely to develop 
some of these problems (e.g., cardiovascular disease) as late effects, the benefits of weight 
control are obvious.  Indeed, these are conditions for which there is proven benefit of weight 
management.  Thus, it is of paramount importance to encourage breast cancer survivors to 
achieve and maintain a weight that is within the ideal range in an effort to promote overall 
health.40  
 The influence of obesity on specific comorbidities, acute symptoms and late effects 
In addition to cardiovascular disease and diabetes, which top the list as prevalent and serious 
health concerns for breast cancer survivors, and which can impede progress to full recovery, 
there are several other conditions and treatment-associated sequelae (see below).  These also are 
conditions for which obesity has been linked to adverse outcomes. While weight management is 
likely to offer a means to reduce these risks, at present no data exists to definitely support this 
approach.        
 
Surgical Risk 
Surgery is the mainstay of breast cancer treatment, and is either performed as the initial form of 
curative treatment, or performed after neoadjuvant therapy.  While obesity does not have a 
significant impact on some of the surgeries for breast cancer that are relatively minor and 
conducted on an outpatient basis (e.g., lumpectomy), it can have adverse consequences on more 
involved procedures.   Mastectomy and axillary node dissection, and especially reconstructive 
surgery can result in poorer surgical outcomes if the patient is obese.  Since 33-54% of women 
receive reconstructive surgery either during or after curative procedures, this is a prevalent 
concern.52 Obesity has long been acknowledged as contributing to increased operating and 
recovery times, more blood loss, poorer healing, and higher infection rates not only for surgery 
in general, 53-55  but also surgeries that specifically involve the breast. 56-58  Most recently, Chen 
et al.56 reported an almost 12-fold increase in the complication rate among obese vs. non-obese 
patients.   
      
Lymphedema 
The risk of lymphedema after breast cancer surgery has been chronicled over several decades,59 
and the results of four large cohort studies consistently show higher risk among women who are 
obese (BMI ≥ 30).60-63   Weight gain occurring after diagnosis has also been suggested as a risk 
factor.64  In a recent prospective cohort of 138 newly diagnosed breast cancer survivors, Ridner 
et al.63 examined the impact of post-operative weight gain on the incidence of lymphedema.  Pre-
operative arm-volume was measured by perometer, with quarterly post-surgical follow-up.  At 
30 months, 27 women (19.6% of sample) had developed lymphedema and this number did not 
differ by weight status using either criterion for lymphedema (i.e., 200 milliliter difference from 
baseline or 10 percent increase in arm volume).  Those who had a BMI ≥ 30 at baseline had a 
higher risk of developing lymphedema (odds ratio = 3.59; 95% CI = 1.42-9.04).  However, a 
general increase in BMI from baseline or increase in BMI to ≥ 30 at 30-months post-surgery was 
not associated with an increased risk of lymphedema. Since most of the sample was overweight 
or obese prior to surgery, it is unknown whether increases in weight status among normal weight 
women would yield similar findings.  Further, findings from several prospective cohort studies 
have demonstrated no relationship between higher body mass index and lymphedema risk. 
Nonetheless, higher body mass index has never been associated with reduced risk and the 
importance of maintaining healthy body weight in relation to other breast cancer outcomes is 
clear.65-67 
Further evidence for the role of body weight on lymphedema is provided by a single 12-
week intervention study with 24 breast cancer survivors. The weight loss intervention (individual 
dietary advice to produce a two pound per week weight loss) was aimed at producing a 
significant reduction in upper extremity lymphedema volume, calculated from arm 
circumference measures. Compared to the control group, women in the intervention group lost 
on average 3.3 kg and had a significant reduction in swollen arm volume on the affected side.68  
 
Fatigue 
 While fatigue is reported as a longstanding and well-documented issue among women 
with breast cancer, only recently have associations between body weight and fatigue been 
investigated.  In several cross-sectional studies that range from 9 months to 18 years post-
diagnosis, women who were overweight and obese, or those who gained weight post-diagnosis 
were more likely to report fatigue.62;69-71  In a recent longitudinal study of 304 early stage breast 
cancer survivors, women who were obese prior to the start of adjuvant treatment were more 
likely to develop cancer-related fatigue at 42-months post-treatment than those with BMIs < 
30.72  In a small cross-sectional study of older breast cancer survivors, higher body fat, as 
measured by dual-energy x-ray absorptiometry also was significantly and positively associated 
with higher levels of fatigue.  
 
Arthralgias 
 While obesity is strongly linked to the development of osteoarthritis and joint pain in 
non-cancer survivors,73 information on the impact of obesity on arthralgia or joint pain secondary 
to breast cancer is limited and conflicting.   Mao et al. 74 found no association between BMI and 
arthralgia in a cross-sectional study of 300 postmenopausal breast cancer survivors, whereas in a 
sample of 200 postmenopausal women receiving adjuvant aromatase inhibitors (AI) for early 
stage breast cancer, Crew et al. 75 found that 34% of overweight women (BMI 25-30) reported 
AI-related joint pain and stiffness compared to 57% of normal weight (BMI <25) and 54% of 
obese (BMI >30) patients.  In contrast, the largest study conducted to date (9366 postmenopausal 
breast cancer survivors randomized to anastrozole or tamoxifen), Sestak et al.76 found more joint 
symptoms in obese women compared to those who were overweight or normal weight. 
 
Bone Health 
 In contrast to several other health conditions for which overweight and obesity serve as 
risk factors, for bone health a higher BMI is consistently associated with higher bone mineral 
density and a decreased risk of fracture.77-79   Indeed, a low BMI (< 20) is one of eight fracture 
risk factors for breast cancer survivors identified in a systematic review by Hadji et al.80  Thus, 
weight loss pursuits by women who have had breast cancer should be to seek BMI within the 
healthy weight range (BMI 20-25) and not below 20. Most importantly, weight bearing exercise 
plays an integral role in  weight loss programs and should be included to ensure preservation of 
bone mass as body weight declines.81;82 
 
Other Sequelae of Breast Cancer and its Treatment  
In addition to the sequelae listed above, women who have been treated for breast cancer either 
with chemotherapy or hormonal therapy often experience vasomotor symptoms (i.e., hot flashes) 
that significantly reduce their quality of life.   A recent study by Su et al.83 among 300 breast 
cancer survivors, found that among those who gained more than 10 pounds post-diagnosis 
(roughly a third of the sample), the risk of hot flashes, as well as increased severity of hot flashes 
was more than double that of those who were weight stable.  While the utility of both regular 
exercise and weight loss has been suggested for the treatment of this prevalent side effect, 
consensus has yet to be achieved and more research is needed.84;85  As noted in the beginning of 
this section, cardiovascular disease and diabetes are prevalent co-morbidities for which breast 
cancer patients, particularly overweight or obese women, are at greater risk.40  These 
comorbidities may be present at the time of diagnosis, but these diseases oftentimes appear 
afterwards, particularly since they are weight dependent and weight gain is common. Currently, 
it is difficult to disentangle whether downstream sequelae, such as peripheral neuropathy (seen 
also with uncontrolled diabetes), exacerbates chemotherapy-induced peripheral neuropathy, or if 
these events are totally independent.  Similarly, it is difficult to ascertain whether underlying and 
uncontrolled cardiovascular disease contributes to chemotherapy-induced cardiotoxicity.  Given 
that the study of cancer survivorship is relatively new, at this juncture it is unknown whether 
overweight and obesity contribute independently to the sequelae of breast cancer treatment, or 
whether these events are mediated primarily by these other diseases.64;86 Since weight 
management is a key and proven therapy for both diabetes and cardiovascular disease, it is 
speculated that if these conditions are controlled, it also may help prevent downstream 
morbidity.    
 
Weight Management:  
           Two organizations (the American Cancer Society [ACS] and the World Cancer Research 
Fund- American Institute of Cancer Research [WCRF-AICR]) provide diet and exercise 
guidelines for cancer survivors; at the forefront of each set of guidelines is the recommendation 
for weight control.40;87 These guidelines emanate from the growing body of research just 
reviewed that suggests that obesity is a poor prognostic factor for cancer, as well as the 
overwhelming evidence that weight control is important for managing prevalent co-morbid 
conditions.  Currently, it is suggested that until more is known, the strategies endorsed for weight 
management in normal populations be applied to cancer survivors.40 Thus, interventions that 
bank on a  three-part approach of diet, exercise and behavioral therapy are recommended.88 
Women who are normal weight at diagnosis should be apprised of the risk of weight gain, and 
encouraged to consume diets which are nutrient-dense, but limited in the amounts of simple 
sugars and added fats which increase caloric load, as well as to pursue aerobic and strength 
training exercises (to burn energy and avoid sarcopenia).38;40;87 For women who are overweight 
or obese these strategies also can be pursued to avoid additional weight gain; however more 
structured approaches may be necessary if weight loss is the goal.89  Indeed, moderate weight 
loss of up to two pounds per week can be pursued safely at any time post-diagnosis, assuming 
that women are appropriately monitored and approval is given by the oncology care physician.40 
Many women with breast cancer however elect to delay concerted efforts toward weight loss 
until active treatment is complete. 
             Several interventions to avoid increased adiposity and adverse, treatment-associated 
changes in body composition,90-93 as well as to promote weight loss among overweight and obese 
women with breast cancer have been tested over the past two decades and are summarized in 
Table 1.94-102  These trials have been conducted among women at various stages in the cancer 
care continuum, from those who are newly diagnosed and actively receiving treatment to those 
who are long-term cancer survivors, and in samples that are as small as 10 to as large  as 289.  
Overall, these studies have shown success, with greater improvements in body weight status 
resulting from interventions that use multicomponent approaches involving diet, physical activity 
and behavior modification.  For example, in the trial by Loprinzi et al.91 in which dietary 
restriction was pursued without a physical activity component, there were negligible differences 
between the intervention and control groups, whereas the multicomponent interventions of 
Goodwin et al.93 and Mefferd et al.94 resulted in greater weight loss and differences between the 
intervention and control arms.  While the magnitude of weight loss may appear greater with 
clinic-based interventions, it is difficult to disentangle whether such interventions are actually 
superior or whether these trials attract self-selected samples that are more motivated to adhere to 
weight loss regimens.  An example of this discrepancy is provided by the two feasibility studies 
of Demark-Wahnefried et al.90;92 in which a clinic-based study resulted in improvements in body 
composition that appeared far superior to those with a home-based program.  However, the 
clinic-based program was  successful in only accruing highly motivated, upper socio-economic 
women who were willing to attend thrice weekly exercise sessions (and who tended to have 
higher physical activity levels at baseline),92 whereas the home-based program attracted a diverse 
group of women who were exercisers and non-exercisers alike.90  In general, however, most of 
these trials show improvements in body weight or body composition status, and also 
improvements in diet and physical activity behaviors, various biomarkers (e.g., serum lipids, 
cytokines and adipokines), and clinical outcomes (e.g., quality of life and physical functioning).  
More study is needed to discern the optimal timing of interventions, sequencing of behavioral 
components, and the impact of weight loss on breast-specific and overall health outcomes, as 
well as health care costs.   
 
The need for prospective surveillance of body weight (prospective model) 
As highlighted earlier, the majority of women diagnosed with breast cancer are overweight or 
obese at diagnosis, and all women (irrespective of baseline weight) are at risk of weight gain 
post-diagnosis.  Thus, there is a real need to educate women about the potential implications of 
weight and weight gain on disease and treatment outcomes, as well as adverse effects.  Regular 
prospective surveillance, commencing pre-treatment, as suggested by the prospective 
surveillance model described by others in this supplement issue of Cancer, is the key to initiating 
relevant discussions around body weight.  Body weight, and ideally more direct measures of 
body fat afforded by anthropometrics, bioelectric impedance, or other testing, should be 
objectively measured at clinical visits to ensure women have an accurate representation of their 
body weight and to demonstrate that weight is an outcome of interest to their health care team.  
All women, regardless of initial BMI, should be provided with information on weight 
management strategies during treatment  Regular assessment, suggested monthly and/or during 
each routine follow-up visit until treatment cessation, will enable identification of those women 
experiencing steady or rapid weight gain, as well as those women already overweight or obese 
who are not achieving weight loss.   Such regular measurement will allow for additional, early 
and individualized, intervention as needed, likely reducing the extent of weight gains and 
optimizing the ability for weight loss.  For women who are overweight or obese (BMI > 25), 
weight maintenance or weight loss strategies during adjuvant or following adjuvant treatment 
should be encouraged, with the goal of weight loss toward achieving a healthy body weight  by 2 
years post-adjuvant treatment. Furthermore, the integration of regular weight-bearing and 
strength exercises into these strategies is crucial for optimizing muscle mass and preserving bone 
health. Importantly, it is clear that there are many contributing factors to a woman’s weight at 
diagnosis and weight gain post-diagnosis.  Therefore, weight should be considered an important 
outcome to measure throughout and beyond all forms of breast cancer treatment, rather than be 
viewed as an outcome of interest for specific subgroups of women based on treatment choices or 
patient characteristics.   
 
Summary 
It can be expected that higher proportions of women will be overweight or obese at the point of 
diagnosis as the worldwide pandemic of obesity spreads.41 As such it is of paramount importance 
that health care messages to avoid weight gain during adulthood as a means of cancer prevention 
(particularly among high risk women) be disseminated.  While it is currently unknown whether 
post-diagnosis weight loss can improve prognosis and disease-free survival, evidence suggests  
that weight management is key to controlling prevalent co-morbid conditions in this patient 
population. Thus, health care professionals should encourage weight management at all phases of 
the cancer care continuum as a means to avoid adverse sequelae and late effects, and improve 
overall health.          
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Table 1: Intervention studies specifically directed toward weight management or weight loss in women with breast cancer  
Authors Sample Design Intervention Frequency/duratio
n 
Results  
Prevention of weight gain or gains in adiposity 
Loprinzi 
et al. 1996 
85 
107 Premenopausal 
patients actively 
receiving adjuvant 
chemotherapy. 
2-arm 
(initial 
oncologist 
advice vs. 
regular 
dietician 
counseling) 
Randomized 
Control 
Trial (RCT) 
Individual dietician 
counseling to maintain 
weight. No reported theory. 
Monthly for 6 months Median weight changes at 6 month follow-up were  
2.0 kg in the experimental group vs. 3.5 kg in the 
control group (N.S.). The median changes in average 
calorie consumption were reductions of 120 vs. 46 
kcal/day on weekdays & 196 versus 20 kcal/day on 
weekends for the experimental & control groups, 
respectively 
Demark-
Wahnefrie
d et al. 
2002.86  
10 Premenopausal, 
stage I & II breast 
cancer patients 
actively receiving 
adjuvant 
chemotherapy. Mean 
age 42, 100% 
Caucasian 
Single arm 
feasibility 
study 
compared to 
historic 
controls 
Clinic-based aerobic & 
strength training exercise + 
healthy diet (<20% kcal 
from fat, 5+ serving fruits & 
vegetables/day, & 1,200-
2,500 mg. calcium/day).  
Social Cognitive Theory. 
Thrice weekly, 
graduated intensity 
individual sessions 
for 6-months 
Compared to historic controls, intervention 
participants experienced the following changes in 
body composition: Total body mass +2.2 (0.4) vs. -2.0 
(1.3) kg. (p=.02); % Body fat: +1.8 (1.6) vs. -1.3 (1.2) 
(p=.002); Fat mass: +2.0 (0.3) vs. -1.2 (1.5) kg. 
(p=.04); & Lean body mass: -0.3 (.01) vs. +0.1 (1.5) 
kg. (N.S.).  Attrition 10%. 
Demark-
Wahnefrie
d et al. 
2008.84 
90 newly diagnosed 
premenopausal 
women with Stage I-
IIIA breast cancer 
actively receiving 
adjuvant 
chemotherapy. Mean 
age = 41.8.   
3-arm 
feasibility 
trial  
Mailed materials & 
telephone counseling. All 3 
arms counseled on 1,200-
1,500 mg of calcium/day. 
Arms 2 & 3 received 
exercise counseling 
promoting aerobic exercise 
(>30 minutes/day at least 3 
days/week) & resistance 
training for legs & lower 
body.  Arm 3 also received 
counseling on diet with 
<20% of kcal from fat & at 
least 5 daily servings of 
fruits & vegetables.  Social 
Cognitive Theory + Health 
Belief Model. 
All participants 
received written 
mailed materials & 
telephone counseling 
(14 sessions over the 
6 month study 
period). 
Measures of adiposity were generally lower in the 
study arm that received all intervention elements (diet 
+ exercise), though the only significant difference was 
in extremity adiposity, i.e., 0.7% vs. 1.2% vs. 0.1%, in 
control vs. exercise alone vs. exercise + diet arms, 
respectively (p=.047). Fat and fruit & vegetable 
change scores differed significantly in the diet + 
exercise arm; though no differences in change scores 
were observed for physical activity.  No differences 
between study arms were observed for quality of life, 
anxiety, depression, serum lipids, sex hormone 
binding globulin, insulin, proinsulin, C-reactive 
protein, interleukin-1B, or tumor necrosis factor 
receptor- II. Targeted accrual was achieved with 8.8% 
drop-out. 
Djuric et 
al.102 
40 newly diagnosed 
adult women (over age 
2-arm 
feasibility 
The Written Material Group 
received a My Pyramid Plan 
The Written Material 
Group received 
The telephone counseling arm reported significant 
improvements in physical activity over the time 
18) with Stage I-IIIA 
breast cancer either 
scheduled or within 2 
weeks of initiating 
chemotherapy.  Mean 
age = 52.2   
trial and brochures on diet and 
exercise from the American 
Cancer Society.  The 
Telephone Counseling 
Group received Written 
Materials and Instruction by 
a Registered Dietitian who 
used concepts from Social 
Cognitive Theory and 
Motivational Interviewing 
materials through the 
mail; the Telephone 
Counseling Group 
received variable 
contact weekly 
initially and then 
monthly toward the 
end of the 12 month 
study period (19 
contacts in total) 
period; no such effects were observed in the written 
material group (between group differences were not 
presented).  Few differences existed in measures of 
adiposity and no differences were observed in blood 
pressure or biomarkers (insulin, leptin, C-reactive 
protein, C-peptide, glucose, or carotenoids) over time 
in either of the groups.  Targeted accrual was achieved 
with 25% drop-out.   
Prevention of weight gain and promotion of weight loss 
Goodwin 
et al. 
1998.87 
61 women with newly 
diagnosed 
locoregional breast 
cancer (BMI= 20-35), 
100% Caucasian 
1-arm Phase 
II trial  
Multicomponent 
intervention that intervened 
on diet, aerobic physical 
activity & behavior 
modification.  Normal 
weight women received 
guidance on weight 
maintenance whereas 
overweight & obese 
women received 
instruction on weight loss 
Weekly for 10 weeks 
& monthly for the 
remainder of the 1-
year study period 
Mean weight loss was 0.53 ± 3.72 kg. Weight loss 
was greatest in initially overweight women (-1.63 ± 
4.11 kg & in those not receiving chemotherapy  (-2.15 
±2.83 kg). 70.9% met predefined criteria for success. 
Aerobic exercise increased significantly during the 
intervention (p = 0.00005) & was the strongest 
predictor of success (OR 1.73 for each additional 30 
minutes of exercise weekly, p = 0.003). Changes in 
caloric intake were not significant, but fat intake 
decreased, & fibre & carbohydrate intake increased 
significantly. Eating behavior & psychological status 
improved significantly.  10% attrition 
Promotion of weight loss 
de Waard 
et al. 
1993.89 
102 Obese post-
menopausal breast 
cancer patients who had 
newly completed 
radiation therapy.  
100% Caucasian. 
2 arm 
(interventio
n vs. usual 
care) 
feasibility 
RCT in 5 
hospitals in 
Poland &the 
Netherlands 
Individual dietary & 
behavior modification 
counseling 
Initial counseling 
with variable follow-
up for a 1-year period 
At 1-year follow-up the median weight loss was 6 kg 
in the experimental arm.  Further follow-up in the 
Netherlands at 3 years suggested that this weight loss 
was durable.  This trial began as a fully-powered RCT 
to test the impact of weight loss as an adjuvant 
therapy, but was downgraded to a feasibility trial due 
to recruitment issues (oncologists failed to 
acknowledge weight control as an issue) & the 
introduction of Tamoxifen.  
Djuric et 
al. 
2002.90 
48 Breast cancer 
survivors (BMI = 30-
44). 73% Caucasian, 
mean age 51.7 years. 
Pilot 4-
armed RCT 
(+/-
individualiz
ed approach 
+/- Weight 
Watchers® 
The intervention relied 
heavily on dietary 
counseling with some 
behavior modification.  The 
Weight Watcher® arms 
encouraged physical activity.
Variable contact 
throughout the 1-year 
study period with 
weekly contact in 
those assigned to 
Weight Watchers®. 
Individualized 
dietician contact was 
weekly for the 1st 3 
Weight change (mean + SD) after 12 months was as 
follows: +0.85 + 6.0 kg in the control group, -2.6 + 
5.9 kg in the Weight Watchers® group, -8.0 + 5.5 kg 
in the individualized group, and -9.4 + 8.6 kg in the 
group receiving both .  Weight loss was 
significantly related to frequency of attendance & 
attendance was more frequent in the group 
receiving both interventions.  Secondary analyses 
by Jen et al.91 found significantly decreased levels 
months, biweekly for 
months 3 to 6, & 
monthly thereafter. 
of leptin & cholesterol in the comprehensive 
group.   
Mefferd 
et al. 
2006.88 
85 Overweight or obese 
breast cancer survivors 
diagnosed with stage I-
IIIa breast cancer 
within 14 years.  Mean 
age 56 years, 93% 
Caucausian. 
2-arm 
(experiment
al vs. usual 
care) RCT  
Multi-component weight 
management intervention 
involving dietary, exercise, 
behavior modification & 
cognitive restructuring. 
Weekly group classes 
for 4 months 
supplemented with 
telephone counseling  
% Change in body weight was -0.6% vs. -6.8% in the 
usual care & experimental arms, respectively.  
Significantly greater decreases were observed in the 
experimental arm in BMI, waist & hip 
circumferences, & total body & % body fat.  No 
differences were noted in lean body mass.  Attrition 
rate 11%.  Secondary analysis by Pakiz et al.92 
suggests significantly decreased TNFlevels in the 
intervention arm & a trend toward lower IL-6. 
Shaw et 
al.64 
24 Breast cancer 
survivors at least 12 
months out from 
curative treatment with 
documented 
lymphedema.  Median 
age 60. 
RCT with 
assignment 
to a booklet 
on healthy 
eating 
(attention 
control) or 
dietary 
intervention,
Dietitian delivered weight 
loss intervention that 
promoted a restriction in 
kcal intake of 1,000 
kcal/day.  Dietary intake was 
monitored. 
12-week intervention A decrease in weight of 3.3 + 2.6 kg was 
observed in the intervention group compared to 0 
+ 2.97 in the control group.  Significant decreases 
were also observed in BMI, kcal intake & fat 
intakes. There was a significant difference in 
excess arm volume between the control group & 
the weight reduction 
Group (P <.003).12.5% attrition. 
Djuric et 
al. 
2009.93 
24 African American 
breast cancer (Stages I-
IIIA) survivors. BMI 
30-45. Mean age=55.   
Feasibility 
study of diet 
counseling  
vs. diet + 
spirituality 
counseling. 
Weight Watchers® approach 
+/-spirituality counseling 
(12-step approach 
Weekly classes for 
the 1st 3 months, 
biweekly sessions 3-6 
months & monthly 
sessions for 
remainder of 18 
month program. 
No between arm differences in weight, but 
significantly greater improvements in vegetable intake 
(p=.013) & spirituality (p=.024) in the Diet + 
Spirituality arm. 8% attrition. 
Stolley et 
al. 
2009.94 
23 African American 
breast cancer 
survivors, mean age 
51. 
1-arm 
feasibility 
trial 
Multicomponent weight 
loss intervention that 
included tailored dietary, 
physical activity & 
behavioral instruction.  
Social Cognitive Theory 
& Health Belief Model. 
Twice weekly 
classes for 6 
months. 
A significant (p<.001) decrease was observed in 
weight (mean change  −5.57 (−8.63 to −2.51) pounds, 
with a corresponding decrease in BMI.  A significant 
decrease in dietary fat & increases in dietary fiber & 
vegetable intakes, as well as an increase in vigorous 
physical activity was observed. 13% attrition 
Morey et 
al.  
2009.95 
641 older, 
overweight, long-
term survivors of 
breast (n=289), 
prostate (n=261), and 
colorectal (n=91) 
2-arm RCT 
Diet-
exercise 
intervention 
vs. wait list 
control. 
Telephone counseling & 
mailed print material-
based diet & exercise 
intervention based on 
Social Cognitive Theory 
& the Trans-theoretical 
12 month 
intervention 
(personally-tailored 
workbook & 
quarterly 
newsletters, 15 
Weight loss was greater (2.06 kg for intervention 
vs. .92 kg for control, p<.001).  At 12 months, 
physical function declined less rapidly in the 
intervention arm (−2.15; 95% confidence interval 
[CI], −0.36 to −3.93), compared to the control 
arm (−4.84; 95% CI, −3.04 to −6.63) (p=.03). 
cancer. Mean age=73. 
Mean years since 
diagnosis=9. 89% 
Caucasian.  
Model. Goals set at 15 
minutes strength training 
every other day, 30 
minutes/day endurance 
exercise, 7-9 servings/day 
fruits & vegetables, 
reduce fat to 10% of 
energy intake, 10% weight 
loss. 
telephone sessions 
(lasting 15-30 
minutes) & 8 
prompts).  
Physical activity, dietary behaviors, & overall 
quality of life improved significantly in the 
intervention group, compared with control. 13% 
attrition. 
 
 
 
